A study of more than 150,000 men with prostate cancer found that a certain hormone treatment is linked with increased risks of dementia and Alzheimer’s.
There’s a 20% higher chance of having dementia for older men who have taken the prostate cancer treatment, according to the research study from JAMA Network.
That drug treatment, called androgen deprivation therapy (ADT), is used to suppress male hormones (like testosterone) that can help to spread prostate cancer in the body.
The research study looked at over 150,000 men, age 66 or older, that had been diagnosed with prostate cancer. Researchers monitored participants over a period of at least 10 years after diagnoses.
Among those that were given ADT to treat their prostate cancer, there was a 20% increase in risk of dementia and a 14% higher risk of Alzheimer’s disease.
“Our results suggest that clinicians need to carefully weigh the long-term risks and benefits of exposure to ADT in patients with a prolonged life expectancy and stratify patients based on dementia risk prior to ADT initiation,” the researchers wrote in their study.
The study also found that the risk of dementia and Alzheimer’s increased with the number of doses of ADT patients were given.
Written by Paige Leskin for Business Insider ~ July 6, 2019
FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U. S. C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml